The effect of newer antiarrhythmic drugs on defibrillation threshold by Tacker, W A et al.
Purdue University
Purdue e-Pubs
Weldon School of Biomedical Engineering Faculty
Publications Weldon School of Biomedical Engineering
1980








See next page for additional authors
Follow this and additional works at: http://docs.lib.purdue.edu/bmepubs
This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact epubs@purdue.edu for
additional information.
Recommended Citation
Tacker, W A.; Niebauer, M J.; Babbs, Charles F.; Combs, W J.; Hahn, B M.; Barker, M A.; Seipel, J F.; Bourland, J D.; and Geddes, L A.,




W A. Tacker, M J. Niebauer, Charles F. Babbs, W J. Combs, B M. Hahn, M A. Barker, J F. Seipel, J D. Bourland,
and L A. Geddes





The effect of newer antiarrhythmic drugs on defibrillation 
threshold 
 
W. A. TACKER, MD, PhD; M. J. NIEBAUER, MS; C. F. BABBS, MD, PhD; W. J. COMBS; 
B. M. HAHN; M. A. BARKER; J. F. SEIPEL; J. D. BOURLAND, PhD; L. A. GEDDES, PhD 
 
 






This study was conducted to determine the effects of clofilium phosphate and bretylium tosylate 
on ventricular defibrillation threshold. Dogs were anesthetized with pentobarbital and subjected 
to repeated fibrillation-defibrillation episodes. Defibrillation thresholds were determined at 15-
min intervals using underdamped 5-6 msec sinusoidal current shocks, from 30 min before drug 
injection to 120 min after injection. Eight dogs were given clofilium phosphate (0.34 mg/kg, iv). 
Another 10 dogs were given bretylium tosylate (10.0 mg/kg, iv). Both drugs lowered 
defibrillation threshold from 15-90 min after injection. The maximum clofilium effect was a 31% 
decrease in threshold current and a 54% decrease in threshold energy. The greatest decrease in 
defibrillation threshold produced by bretylium was 16% for current and 31% for energy. These 
drug induced changes in defibrillation threshold are of potential clinical benefit, if they occur in 
human subjects at doses that are effective for control of ventricular arrhythmias. 
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The authors have shown recently that three major antiarrhythmic drugs (quinidine, phenytoin, 
and lidocaine) increase the threshold shock strength required for ventricular defibrillation in 
dogs.
1
 This effect presents a potential clinical problem, because fibrillation may still occur after 
these antifibrillatory drugs have been given, and immediate electrical defibrillation is required. In 





An experimental drug, clofilium, developed by Eli Lilly and Company, seems to be the first 
member of a new class of antiarrhythmic drugs with a mechanism of action quite different from 
either quinidine, phenytoin, or lidocaine. This new compound probably blocks outward 
potassium current through the cell membrane and has been shown to produce chemical 
defibrillation in the absence of a defibrillator countershock.
3
 Such spontaneous defibrillation is 
tantamount to decreasing electrical defibrillation threshold to zero. 
 
Bretylium tosylate has recently been approved for use as an antiarrhythmic in the United States 
and also has different pharmacological properties than the drugs mentioned previously.
4
 
Bretylium, like clofilium, has been reported to produce chemical defibrillation in the absence of 
a defibrillator countershock.
5
  Because of the apparent ability of these two agents to make 
defibrillation easier, and because of their unique pharmacological characteristics, the authors 
have investigated the effects of intravenous clofilium phosphate and bretylium tosylate on 




Eighteen mongrel dogs weighing from 9 to 22 kg were studied. Each dog was anesthetized with 
pentobarbital sodium (30 mg/kg, iv) and intubated to maintain a patent airway. Pentobarbital 
anesthesia was selected because it does not itself alter the defibrillation thresh- old.
6
 Lead II ECG 
was monitored using subdermal pin electrodes. A femoral vein was catheterized for 
administration of additional doses of pentobarbital to maintain anesthesia, as well as for 
administration of the antiarrhythmic drugs. A femoral artery was catheterized for direct 
measurement of blood pressure. A bipolar stimulating electrode mounted on a catheter was 
passed from the right jugular vein into the right ventricle to initiate fibrillation. Low resistance 
electrolytic gel and 10-cm diameter electrodes for external defibrillation were applied to the 
shaved right and left chest walls and the electrodes sutured in place. The defibrillator used in this 
study produced a slightly underdamped sinusoidal current waveform.
7
 The duration of the 
current pulse was maintained between 5-6 msec for each dog by varying the capacitance of the 
defibrillator from 20-40 microfarads. The inductance was set at 63 millihenrys, and the internal 
resistance of the defibrillator was 3.5 ohms. Voltage and current were displayed on a dual trace 
storage oscilloscope (Tectronix Inc., Beaverton, OR). The apparent impedance of the chest was 
calculated as the ratio of peak voltage to peak current. Stored energy, Ws, was calculated from 








where; C = capacitance, and E = voltage applied to the capacitor. Delivered energy was 
calculated using the equation 
 
Wd = Ws[Za/(Za + Ri)] 
 
where Wd = delivered energy, Ws = stored energy, Ri = internal resistance of the defibrillator,  
Za = apparent impedance of the subject. 
 
Ventricular fibrillation was produced by 60 Hz electrical stimulation through the transjugular 
stimulating electrode, and confirmed by the ECG and by the loss of arterial blood pressure 
pulses. Test shocks from the defibrillator were delivered at end-expiration and within 30 sec of 
the onset of ventricular fibrillation. If the test shock failed to defibrillate, a backup shock of 
approximately 2 amp/kg body weight was applied to achieve defibrillation. Following 
defibrillation, blood pressure was allowed to return to prefibrillation levels before the next 
fibrillation-defibrillation trial. A defibrillation threshold value was defined as a current intensity 
which defibrillated, but was no more than 10% greater than a current that did not defibrillate. 
Only test shocks (and not backup shocks) were used to establish threshold values.  
 
Defibrillation threshold values were determined at 15-min intervals for 30 min before and 120 
min after administration of test drugs. After measurement of three predrug thresholds, 0.34 
mg/kg (1.0 mole/kg) clofilium phosphate (Eli Lilly and Co.) was administered to 8 dogs as an 
intravenous bolus via the femoral vein. Similarly, in another 10 dogs 10.0 mg/kg bretylium 
tosylate (Bretylol; Arnar-Stone Laboratories Inc.) was administered as an intravenous bolus and 
defibrillation threshold was monitored. These doses were selected because they are effective in 
preventing ventricular fibrillation in dogs. The three predrug threshold determinations for each 
dog were averaged and the mean values equated to 100% of control for each dog. Individual 
postdrug values were expressed relative to these predrug control values. The resulting 
normalized data from all of the animals were then averaged and the Mann-Whitney statistic 
calculated to test the null hypothesis that the various postdrug thresholds were the same as the 




Clofilium phosphate and bretylium tosylate clearly depressed the current (Figs. 1A and 1B) and 
energy (Figs. 2A and 2B) thresholds for ventricular defibrillation when given before the onset of 
fibrillation. Energy requirements for defibrillation dropped 54% after clofilium and 31% after 
bretylium. The onset of action was rapid with both drugs, producing near maximal depression of 
threshold 15 min after injection. In addition to the effect upon threshold, the authors observed 
that in some subjects that the time required for blood pressure to recover was prolonged after 
administration of bretylium. After clofilium administration, the authors did not observe slow 







FIG. 1.  A. Effect of 
intravenous clofilium 
phosphate (0.34 mg/kg, given 
at t = 0) on current threshold 
for ventricular defibrillation in 
8 dogs (mean ± SEM). The 
absolute current threshold 
value corresponding to 1.00 on 
the vertical axis was 1.15 
A/kg. All threshold 
depressions after drug injection 
are statistically significant (U 
< 25. p < 0.001). Because of 
the difference in the standard 
deviations of predrug and 
postdrug data, the Mann-
Whitney U-test of significance 
was used to compare postdrug 
values with the predrug values 
in this and subsequent figures.  
 
B. Effect of intravenous 
bretylium tosylate (10.0 
mg/kg, given at t = 0) on 
current threshold for 
ventricular defibrillation in 10 
dogs (mean ± SEM). The 
absolute current threshold 
value corresponding to 1.00 on 
the vertical axis was 0.97 
A/kg. All threshold 
depressions after bretylium 
injection are statistically 
significant (U < 93, p < 0.05) 














FIG. 2.  A. Effect of intravenous 
clofilium phosphate (0.34 mg/kg. 
given at t = 0) on energy threshold 
for ventricular defibrillation in 8 
dogs (mean ± SEM). The absolute 
threshold value corresponding to 
1.00 on the vertical axis was 2.59 
J/kg. All threshold depressions 
after drug injection are statistically 
significant (U < 18, p < 0.0003 ).  
 
B. Effect  of intravenous bretylium 
tosylate (10.0 mg/kg, given at t = 
0) on energy threshold for 
ventricular defibrillation in 10 dogs 
(mean ± SEM). The absolute 
threshold value corresponding to 
1.00 on the vertical axis was 1.77 
J/kg. All threshold depressions 
after bretylium injection are 
statistically significant (U < 75. 










This report is the first to describe depression of defibrillation threshold by antiarrhythmic drugs. 
This effect is in direct contrast to the effects of quinidine, phenytoin, and lidocaine, all of which 
increase defibrillation threshold when given before the onset of fibrillation.
1
 The apparent 
advantage of bretylium to decrease defibrillation threshold must be balanced against the apparent 
loss of hemodynamic recovery that we observed after it was given. Bretylium possesses 
antiadrenergic and hypotensive actions associated with depletion of norepinephrine from 
peripheral adrenergic nerve endings.
4
 In accordance with this known mechanism, some subjects 
treated with bretylium may not be able to recover as well from fibrillation-defibrillation episodes 
because of less effective autonomic reflexes. In a clinical study, however, Haynes et al.
8
 found 
no differences in resuscitative results (short term or long term survival) for patients after use of 
bretylium as compared to lidocaine. 
 
The 0.34 mg/kg dose of clofilium decreased the energy threshold for defibrillation by 50%, but 
did not seem to adversely affect cardiovascular function. To the knowledge of the authors, this 
ability to depress defibrillation threshold without toxic side-effects is a unique property of 
clofilium. The digitalis glycoside, ouabain, may produce a similar (up to 50%) depression of 
defibrillation threshold,
9
 but only at doses approaching the LD50. Likewise, profound 
hyperkalemia (8-13 mEq/liter) can depress defibrillation threshold,
10
 but only in conjunction 
with severe cardiac dysrhythmias and weakening of cardiac contractility. 
 
The elevation of defibrillation threshold by standard antiarrhythmic drugs
1
 may explain, in part, 
the lower defibrillation success rate for in-hospital versus out-of-hospital patients.
11-15
 The 
contrasting depression of defibrillation threshold by the newer antiarrhythmc drugs in this study 
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